Inhibikase Therapeutics IKT
NASDAQ IKT
$1.63 +0.08 (+5.16%)
At close: Nov 11, 2026 · 4:00 PM EST

Inhibikase Therapeutics (IKT) Change in Intangibles (2025)

Updated

Inhibikase Therapeutics (IKT) reported Change in Intangibles of $438,624 for FY2025.

Analysis

Inhibikase Therapeutics (IKT) Change in Intangibles (2025) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change Intangibless (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn 4.06 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn 995.00 Mn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn -
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn -
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn -7.20 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn -
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn -
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn -
10 Inhibikase Therapeutics 281.11 Mn -420.36 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2025 438,624.00
API Access

Inhibikase Therapeutics Change in Intangibles API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=change-in-intangibles&ticker=IKT&period=max&api_key=YOUR_API_KEY